copaydosingefficacyresourcesafety

THIS SITE IS INTENDED FOR US AUDIENCES ONLY

Co-pay and Patient Support

Support services for Otezla® (apremilast) patients

OTEZLA SUPPORTPLUS™ – YOUR SUPPORT NETWORK, INCLUDING RESOURCES FOR YOU AND YOUR PATIENTS

Otezla SupportPlus

This support network includes resources for you and your patients.

  • $0 co-pay enrollment and follow-up*
  • 24/7 access to specially trained nurses
  • Live insurance support
  • Updates on prescription status
  • Shipment of free bridge to maintenance supply during potential reimbursement delays for commercially insured patients
  • Reimbursement support
Banner describing the co-pay program where patients pay zero dollars each month for a prescription
*

Certain restrictions apply; eligibility not based on income, must be 18 years or older. This offer is not valid for persons eligible for reimbursement of this product, in whole or in part under Medicaid, Medicare, or similar state or federal programs. Offer not valid for cash-paying patients. People who are not eligible can call 1-844-4OTEZLA to discuss other financial assistance opportunities.

Get Your Patients 3 for Free

The Otezla Bridge Program offers your commercial patients up to 3 years of Otezla for $0.

Check the “Bridge Rx” option on the Otezla START Form when prescribing.

Logo for the Otezla® Bridge Program

For more information, call Otezla SupportPlus at 1-844-4OTEZLA (1-844-468-3952)

To receive a free bridge supply of Otezla, patients must have an on-label diagnosis and be denied or waiting for coverage. Patients in Massachusetts are not eligible to receive bridge.

Indications & Important Safety Information

Please click here for Full Prescribing Information.

You are leaving the Otezla® (apremilast) website

Do you wish to leave this site?

Are You a
Healthcare Professional?

Getting Otezla Gets Even Easier

8 out of 10commercially insured lives in the US have preferred access with no biologic step required for Otezla® (apremilast)1

Click here for a complete list of plans
Reference: 1. Data on file, Celgene Corporation.
01/18 USII-APR180063